ESTRO 2024 - Abstract Book

S2540

Clinical - Urology

ESTRO 2024

2506

Digital Poster

Ethnicity in prostate cancer: the importance of asking

Jane Shortall 1 , Eliana Vasquez Osorio 1 , Golnoosh Motamedi 1 , Tanuj Puri 1 , Peter Hoskin 1 , Ananya Choudhury 2 , Marcel van Herk 1 , Alan McWilliam 1 1 The University of Manchester, Radiotherapy Related Research, Manchester, United Kingdom. 2 The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom

Purpose/Objective:

Despite high prostate cancer survival rates, favourable prognosis is not equally observed across all populations. Men of black and ethnic minorities are disproportionately affected by prostate cancer, with higher incidence, more aggressive disease, and higher mortality compared to white men 1 . This finding is thought to be caused by a complex combination of socioeconomic, cultural, and genetic risk factors. Despite the need for better understanding and treatment of prostate cancer in ethnic minority men, the area is relatively understudied. Black and ethnic minority men remain largely under-represented in prostate cancer trials, and are noted to be less willing to enrol in trials due to lack of trust of the health care system, poor physician-patient communication, and language barriers 1 – 3 . Further, ethnicity recording in routinely collected hospital data is often incomplete, due to missing data or men choosing not to disclose their ethnicity, which limits the generalisability of studies of cancer in ethnic groups 2,4 .

We investigated, in a large patient cohort, whether ethnicity, or the lack of ethnicity recording, is associated with overall survival in men with prostate cancer treated with curative intent radiotherapy.

Material/Methods:

Data for 1,455 patients was used in this study. Patients were treated with either conformal hypo-fractionated radiotherapy (50Gy in 16 fractions, n=921), IMRT (57Gy/60Gy in 19/20 fractions, n=176) or IMRT plus High Dose Rate brachytherapy boost (37.5Gy in 15 fractions +15Gy, n=360) at a single institution from 2004-2020. Patient and tumour characteristics (age, T-stage, Gleason grade, Androgen Deprivation Therapy (ADT) duration, baseline Prostate Specific Antigen (PSA) and ethnicity) were collected for all patients. Differences in overall survival between A) ethnic groups and B) known vs undisclosed vs missing ethnicity were assessed using Kaplan- Meijer analysis. Undisclosed ethnicity was recorded as National ethnic category code “Z - Not Stated”, where the person has been given the opportunity to state their ethnic category but chose not to5.

Differences in baseline demographics were also assessed (continuous variables: Kruskal-Wallis, categorical variables: Chi-square).